Nov. 6, 2021

When we talked about a single medication that treated multiple defects of diabetes, we used to be referring to 1 pill containing 2 different medications. Good examples of this were Glucovance, which combined glyburide and metformin, or ActoplusMet, which combined pioglitazone and metformin. There were a lot of possible combo products tried, but their use was always tempered by the ability of the fixed dose combinations to accommodate a large group of patients.

This has changed over the years as we have discovered new classes of drugs. This week, our interns look at two of these dual action drugs. Ding Nguyen, PharmD Candidate, University of South Florida, has a feature about sotagliflozin, the first-in-class dual SGLT-1/2 inhibitor, and the use in type 1 and 2 diabetes; and Trina Maglalang RPh, PharmD Candidate 2022 University of Colorado, brings us an update on tirzepatide, the new GLP1-GIP agonist.

Based on the uptake of the SGLT-1’s and GLP-1 in practice today, it makes sense that these new drugs are poised to be blockbusters as soon as they are approved.

 

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief